Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTONISH: Nangibotide in Septic Shock
NCT04055909Phase 2Active, not recruiting
- Sponsor
- Inotrem
- Start
- Nov 2019
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 6
01
Overview
A Phase 2 trial of nangibotide in septic shock, sponsored by Inotrem. Started Nov 2019; status: active, not recruiting.
02
Drugs
nangibotide
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT04055909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055909.